BPD
MCID: BRN056
MIFTS: 60

Bronchopulmonary Dysplasia (BPD)

Categories: Fetal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 38 76 53 59 55 63 73
Bpd 53 59

Characteristics:

Orphanet epidemiological data:

59
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:



Summaries for Bronchopulmonary Dysplasia

PubMed Health : 63 About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube).Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD.Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and chorioamnionitis. An important gene associated with Bronchopulmonary Dysplasia is SCGB1A1 (Secretoglobin Family 1A Member 1), and among its related pathways/superpathways are G-protein signaling RAC1 in cellular process and Immune response IFN alpha/beta signaling pathway. The drugs RespiGam and Procaterol have been mentioned in the context of this disorder. Affiliated tissues include Lung and Lung, and related phenotypes are sleep disturbance and emphysema

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70589Disease definitionBronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.Visit the Orphanet disease page for more resources.

Wikipedia : 76 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.6 CXCL8 ELANE RNASE3
2 chorioamnionitis 30.6 CXCL8 ELANE FLT1 IL1RN
3 newborn respiratory distress syndrome 30.5 CXCL8 ELANE SCGB1A1 SFTPB
4 lung disease 30.4 CXCL8 ELANE RNASE3 SFTPB
5 respiratory failure 30.3 CXCL8 ELANE SCGB1A1 SFTPB
6 pneumonia 30.2 CXCL8 ELANE SFTPB
7 interstitial emphysema 29.9 ELANE FLT1
8 asthma 29.4 CXCL8 ELANE IL1RN ITGAM RNASE3 SCGB1A1
9 pulmonary fibrosis, idiopathic 29.3 CXCL8 ELANE IL1RN SCGB1A1 SFTPB TIMP1
10 pulmonary disease, chronic obstructive 29.3 CXCL8 ELANE RNASE3 SCGB1A1 SFTPB TIMP1
11 borderline personality disorder 11.7
12 pulmonary hypertension, neonatal 11.1
13 pulmonary hypertension 10.8
14 personality disorder 10.7
15 respiratory distress syndrome, infant 10.3
16 patent ductus arteriosus 1 10.3
17 disorganization, mouse, homolog of 10.3
18 respiratory distress syndrome in premature infants 10.3
19 toxicodendron dermatitis 10.2 CXCL8 SELL
20 exudative vitreoretinopathy 1 10.2
21 toxic myocarditis 10.2 CXCL8 SOD1
22 pouchitis 10.2 CXCL8 IL1RN
23 paraquat lung 10.2 SCGB1A1 SFTPB
24 cardiac rupture 10.2 CXCL8 ELANE
25 toxic pneumonitis 10.2 SCGB1A1 SFTPB
26 capillary leak syndrome 10.2 CXCL8 ELANE
27 vascular disease 10.2
28 erysipelas 10.2 ELANE SOD1
29 cyclic neutropenia 10.2 CXCL8 ELANE
30 cryptogenic organizing pneumonia 10.2 CXCL8 TIMP1
31 necrotizing fasciitis 10.2 CXCL8 IL1RN
32 arthus reaction 10.2 ELANE SELL
33 pulmonary hypertension, primary, 1 10.1
34 cerebral palsy 10.1
35 pre-eclampsia 10.1
36 hypoxia 10.1
37 mid-dermal elastolysis 10.1 ELANE TIMP1
38 acute respiratory distress syndrome 10.1 CXCL8 ELANE SFTPB
39 bacterial pneumonia 10.1 CXCL8 ELANE SFTPB
40 adult respiratory distress syndrome 10.1 CXCL8 ELANE SFTPB
41 lung giant cell carcinoma 10.1 CXCL8 TIMP1
42 mild pre-eclampsia 10.1 FLT1 SOD1
43 aseptic meningitis 10.1 CXCL8 IL1RN
44 meconium aspiration syndrome 10.1 CXCL8 SCGB1A1 SFTPB
45 pleural tuberculosis 10.1 CXCL8 TIMP1
46 cohen syndrome 10.1 ITGAM SELL
47 gastroesophageal reflux 10.1
48 bone disease 10.1
49 pneumothorax 10.1
50 bronchiolitis 10.1

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

59 32 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sleep disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0002360
2 emphysema 59 32 hallmark (90%) Very frequent (99-80%) HP:0002097
3 respiratory distress 59 32 hallmark (90%) Very frequent (99-80%) HP:0002098
4 atelectasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100750
5 cough 59 32 hallmark (90%) Very frequent (99-80%) HP:0012735
6 premature birth 59 32 hallmark (90%) Very frequent (99-80%) HP:0001622
7 exercise intolerance 59 32 frequent (33%) Frequent (79-30%) HP:0003546
8 diaphragmatic paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006597
9 respiratory failure requiring assisted ventilation 59 32 hallmark (90%) Very frequent (99-80%) HP:0004887
10 central apnea 59 32 frequent (33%) Frequent (79-30%) HP:0002871
11 tracheobronchomalacia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002786
12 small for gestational age 59 32 hallmark (90%) Very frequent (99-80%) HP:0001518
13 pulmonary sequestration 59 32 occasional (7.5%) Occasional (29-5%) HP:0100632
14 right ventricular hypertrophy 59 32 frequent (33%) Frequent (79-30%) HP:0001667
15 right ventricular failure 59 32 frequent (33%) Frequent (79-30%) HP:0001708
16 chronic lung disease 59 32 hallmark (90%) Very frequent (99-80%) HP:0006528
17 hyperoxemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0012419
18 wheezing 59 32 frequent (33%) Frequent (79-30%) HP:0030828
19 dyspnea 59 Very frequent (99-80%)
20 functional respiratory abnormality 59 Frequent (79-30%)
21 abnormality of lung morphology 59 Very frequent (99-80%)
22 abnormal respiratory system morphology 59 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 ELANE FGF10 FLT1 IL1RN ITGAM RBP4
2 cardiovascular system MP:0005385 9.87 FGF10 FLT1 IL1RN RBP4 SELL SOD1
3 hematopoietic system MP:0005397 9.86 ELANE FGF10 FLT1 IL1RN ITGAM SELL
4 immune system MP:0005387 9.61 ELANE FGF10 FLT1 IL1RN ITGAM SCGB1A1
5 neoplasm MP:0002006 9.02 ELANE SCGB1A1 SELL SOD1 TIMP1

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMedHealth treatment related to Bronchopulmonary Dysplasia: 63

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine.The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs. It helps keep the lungs open so your infant can breathe in air once he or she is born.Corticosteroids also can help your baby's lungs, brain, and kidneys develop more quickly while he or she is in the womb.Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function.These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
RespiGam 18 MedImmune January 1996

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51333-22-3 63006 5281004
3 Beractant Approved Phase 4,Phase 2,Phase 3 108778-82-1
4 Poractant alfa Approved Phase 4,Phase 2,Phase 3,Not Applicable 129069-19-8
5
Caffeine Approved Phase 4,Phase 3,Not Applicable 58-08-2 2519
6
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
9
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
10
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
11
Remifentanil Approved Phase 4,Phase 1,Phase 2 132875-61-7 60815
12
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
13
Nifedipine Approved Phase 4 21829-25-4 4485
14
Labetalol Approved Phase 4 36894-69-6 3869
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
16 Adrenergic beta-Agonists Phase 4,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Adrenergic Agonists Phase 4,Not Applicable
20 Adrenergic beta-2 Receptor Agonists Phase 4,Not Applicable
21 Albuterol Phase 4,Not Applicable
22 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Adrenergic Agents Phase 4,Not Applicable
27 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Pulmonary Surfactants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2
35 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
36 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
37 Purinergic P1 Receptor Antagonists Phase 4,Phase 3,Not Applicable
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Omega 3 Fatty Acid Phase 4,Phase 3,Not Applicable
41 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Lactoferrin Phase 4
43 Vaccines Phase 4
44 Immunoglobulins Phase 4,Phase 3,Phase 2
45 Antibodies Phase 4,Phase 3,Phase 2
46 Immunologic Factors Phase 4,Phase 3,Phase 2
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
48 Betamethasone Valerate Phase 4,Phase 2,Phase 3 2152-44-5
49 Antiemetics Phase 4,Phase 3,Phase 2
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 415)
# Name Status NCT ID Phase Drugs
1 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
2 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
3 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
4 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
5 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
6 Azithromycin in the Prevention of Lung Injury in Premature Newborn Completed NCT03485703 Phase 4 Azithromycin;Placebo
7 Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
8 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
9 A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Completed NCT00201643 Phase 4 Betamethasone or Dexamethasone (2nd course of ACS);Placebo
10 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
11 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV Completed NCT01604447 Phase 4
12 Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates Completed NCT01403623 Phase 4
13 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
14 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
15 Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
16 Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor Recruiting NCT02430233 Phase 4 micronized progesterone 400 mg (Utrogestan)
17 Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome Recruiting NCT02164734 Phase 4 remifentanil
18 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
19 Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
20 Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide Not yet recruiting NCT02853253 Phase 4
21 Intratracheal Budesonide/Surfactant Prevents BPD Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
22 Personalized vs Standardized PN for Preterm Infants >1250g Not yet recruiting NCT03693287 Phase 4 Numeta G13®, BAXTER Spa;Personalized-parenteral nutrition.
23 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
24 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
25 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia Unknown status NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.)
26 Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Unknown status NCT01721655 Phase 2, Phase 3 Spironolactone;Placebo
27 Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane Unknown status NCT01503606 Phase 3 Cefazolin;Clarithromycin;Cefazolin;Clarithromycin
28 Cysteine Supplementation in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
29 Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants Unknown status NCT03024814 Phase 3 Acetaminophen;Dextrose 5
30 Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth Unknown status NCT02678026 Phase 3
31 A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Unknown status NCT02336243 Phase 3
32 Modulation of the Intestinal Flora With the Probiotic VIVOMIXX™ in Pregnant Women at Risk of Metabolic Complications Unknown status NCT02768818 Phase 3
33 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
34 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
35 PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Completed NCT00623740 Phase 3 hydrocortisone;placebo
36 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
37 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
38 Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) Completed NCT00433212 Phase 3
39 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
40 Post-hospitalization Nursing Effectiveness (PHONE) Study Completed NCT00314431 Phase 3
41 Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
42 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
43 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
44 Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed NCT00006401 Phase 3 iNO
45 Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. Completed NCT00188968 Phase 3
46 Surfactant Positive Airway Pressure and Pulse Oximetry Trial Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
47 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Completed NCT01306227 Phase 3 L-Thyroxine;water
48 Vitamin D Supplementation for Extremely Preterm Infants Completed NCT01600430 Phase 2, Phase 3
49 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
50 Premature Infants in Need of Transfusion (PINT) Completed NCT00182390 Phase 3

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM�, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

41
Lung, Brain, Bone, Endothelial, Kidney, Skin, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
2 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate
3 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 1446)
# Title Authors Year
1
Right ventricular function in infants with bronchopulmonary dysplasia and pulmonary hypertension: a pilot study. ( 30419798 )
2019
2
Role of vitamin A supplementation in prevention of Bronchopulmonary dysplasia in extremely low birth weight neonates: A systematic review of randomized trials. ( 29447482 )
2018
3
Bronchopulmonary dysplasia appropriateness as a surrogate marker for long-term pulmonary outcomes: A Systematic review. ( 29843269 )
2018
4
Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment. ( 29374791 )
2018
5
Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More. ( 29328889 )
2018
6
Clinical Outcomes among Diagnostic Subgroups of Infants with Severe Bronchopulmonary Dysplasia through 2 Years of Age. ( 29852508 )
2018
7
Prediction of bronchopulmonary dysplasia development. ( 29895571 )
2018
8
Decreased ZONAB expression promotes excessive transdifferentiation of alveolar epithelial cells in hyperoxia-induced bronchopulmonary dysplasia. ( 29393348 )
2018
9
Aurothioglucose Does Not Improve Alveolarization or Elicit Sustained Nrf2 Activation in C57Bl/6 Models of Bronchopulmonary Dysplasia. ( 29368550 )
2018
10
Predictors of length of stay for initial hospitalization in infants with bronchopulmonary dysplasia. ( 29880793 )
2018
11
Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. ( 29907614 )
2018
12
NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. ( 29977013 )
2018
13
Quercetin attenuates the hyperoxic lung injury in neonatal mice: Implications for Bronchopulmonary dysplasia (BPD). ( 29432836 )
2018
14
A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases. ( 29951473 )
2018
15
Brainstem auditory abnormality in extremely premature babies and the impact of neonatal bronchopulmonary dysplasia. ( 29381192 )
2018
16
Why do children with severe Bronchopulmonary Dysplasia not attend neonatal follow-up care? Parental views of barriers. ( 29420848 )
2018
17
Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence. ( 29363502 )
2018
18
Increased expression of CHOP and LC3B in newborn rats with bronchopulmonary dysplasia. ( 29901175 )
2018
19
Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice. ( 29362947 )
2018
20
L-citrulline supplementation in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infant: A case report. ( 29854406 )
2018
21
Volume targeting levels and work of breathing in infants with evolving or established bronchopulmonary dysplasia. ( 29305407 )
2018
22
Relationship between clinical severity of "new" bronchopulmonary dysplasia and HRCT abnormalities in VLBW infants. ( 29979483 )
2018
23
N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: A prospective observational study. ( 29790673 )
2018
24
Anti-VEGF Antagonists, a Potential Primary Prevention for Bronchopulmonary Dysplasia? ( 29298393 )
2018
25
Ceramides in tracheal aspirates of preterm infants: Marker for bronchopulmonary dysplasia. ( 29346372 )
2018
26
Aerosolized deferoxamine administration in mouse model of bronchopulmonary dysplasia improve pulmonary development. ( 29423017 )
2018
27
Upregulation of Vascular Endothelial Growth Factor in Amniotic Fluid Stem Cells Enhances Their Potential to Attenuate Lung Injury in a Preterm Rabbit Model of Bronchopulmonary Dysplasia. ( 29393249 )
2018
28
A Shared Pattern of I^-Catenin Activation in Bronchopulmonary Dysplasia and Idiopathic Pulmonary Fibrosis. ( 29355514 )
2018
29
Identifying Risk Factors Shared by Bronchopulmonary Dysplasia, Severe Retinopathy, and Cystic Periventricular Leukomalacia in Very Preterm Infants for Targeted Intervention. ( 29621770 )
2018
30
Growth and body composition in preterm newborns with bronchopulmonary dysplasia: a cohort study. ( 29949515 )
2018
31
Intravenous fish oil containing lipid emulsion attenuates inflammatory cytokines and the development of bronchopulmonary dysplasia in very premature infants: A double-blind, randomized controlled trial. ( 29941233 )
2018
32
Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. ( 29941022 )
2018
33
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. ( 29320647 )
2018
34
Neonatal Pulmonary MRI of Bronchopulmonary Dysplasia Predicts Short-term Clinical Outcomes. ( 29790784 )
2018
35
Association between early antibiotic exposure and bronchopulmonary dysplasia or death. ( 29895965 )
2018
36
The changing relationship between bronchopulmonary dysplasia and cognition in very preterm infants. ( 29333635 )
2018
37
The heart of the matter: a vascular hypothesis for bronchopulmonary dysplasia. ( 29809288 )
2018
38
Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia. ( 29935061 )
2018
39
Telomere length was similar in school-age children with bronchopulmonary dysplasia and allergic asthma. ( 29476624 )
2018
40
Incidence of metabolic bone disease in preterm infants of birth weight <1250 g and in those suffering from bronchopulmonary dysplasia. ( 29460805 )
2018
41
Protocol for the REVISIT-BPD Trial, a Randomized Controlled Trial Testing the Effectiveness of an Internet-Based Self-Management Intervention in the Treatment of Borderline Personality Disorder (BPD). ( 30298024 )
2018
42
PRO*BPD: effectiveness of outpatient treatment programs for borderline personality disorder: a comparison of Schema therapy and dialectical behavior therapy: study protocol for a randomized trial. ( 30340474 )
2018
43
Borderline Personality Disorder (BPD): In the Midst of Vulnerability, Chaos, and Awe. ( 30453675 )
2018
44
The aetiology of borderline personality disorder (BPD): contemporary theories and putative mechanisms. ( 29182951 )
2018
45
Vitamin D and IL-10 Deficiency in Preterm Neonates With Bronchopulmonary Dysplasia. ( 30246004 )
2018
46
Bronchopulmonary dysplasia in neonates born to mothers with preeclampsia: Impact of small for gestational age. ( 30248159 )
2018
47
Using clinical and genetic data to predict pulmonary hypertension in bronchopulmonary dysplasia. ( 30267614 )
2018
48
Bronchopulmonary Dysplasia in Very Preterm Infants with Symptomatic Congenital Cytomegalovirus Infection: A Propensity Score- Matched Analysis. ( 30270170 )
2018
49
INTRATRACHEAL ADMINISTRATION OF MESENCHYMAL STEM-CELL-DERIVED EXTRACELLULAR VESICLES REDUCES LUNG INJURY IN A RAT MODEL OF BRONCHOPULMONARY DYSPLASIA. ( 30284924 )
2018
50
Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia. ( 30287068 )
2018

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 ELANE IL1RN ITGAM RBP4 SCGB1A1 SOD1
2 extracellular region GO:0005576 9.7 CXCL8 ELANE FGF10 FLT1 IL1RN RBP4
3 extracellular space GO:0005615 9.4 CXCL8 ELANE FGF10 FLT1 IL1RN ITGAM
4 secretory granule GO:0030141 9.33 ELANE SCGB1A1 SOD1

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.8 ELANE ITGAM RNASE3 SELL
2 regulation of signaling receptor activity GO:0010469 9.73 CXCL8 FGF10 IL1RN TIMP1
3 leukocyte migration GO:0050900 9.7 ELANE ITGAM SELL
4 response to lipopolysaccharide GO:0032496 9.65 ELANE FGF10 SCGB1A1
5 chemotaxis GO:0006935 9.63 CXCL8 FGF10 FLT1
6 blood vessel morphogenesis GO:0048514 9.51 FGF10 FLT1
7 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.4 FGF10 FLT1
8 embryonic digestive tract development GO:0048566 9.37 CXCL8 FGF10
9 response to organic substance GO:0010033 9.33 SCGB1A1 SOD1 TIMP1
10 positive regulation of superoxide anion generation GO:0032930 9.32 ITGAM SOD1
11 induction of positive chemotaxis GO:0050930 9.26 CXCL8 FGF10
12 cytokine-mediated signaling pathway GO:0019221 9.26 CXCL8 IL1RN ITGAM TIMP1
13 female genitalia morphogenesis GO:0048807 8.62 FGF10 RBP4

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.33 CXCL8 IL1RN TIMP1
2 heparin binding GO:0008201 9.13 ELANE FGF10 SELL
3 protease binding GO:0002020 8.8 ELANE SELL TIMP1

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....